October 31, 2002
"The state will pay for medicine, test costs and any necessity for additional staff," Siegel said in announcing the agreement, which extends the CMS contract with the state until Aug. 31, 2003. The money for hepatitis C treatment will be in addition to the millions of dollars the state pays CMS. It was unclear, Siegel said, how much extra money the state would need to spend. Other state corrections departments are finding it can cost $15,000 to $25,000 per hepatitis C-infected inmate to cover testing, monitoring and treatment. The drugs cure about half of treated patients, with viral levels dropping to undetectable levels and remaining there.
New Jersey's current contract with CMS expires today, and the state had received no bids it considered acceptable for a new contract. CMS had asked for an increase that would have raised the cost of prison health care by 30 percent to more than $100 million annually, but it said the state would have to pay extra for hepatitis C care. The state rejected that proposal, arguing that hepatitis C care should have always been covered under the contract. Under the 10-month extension, Siegel said, CMS will receive a 14.7 percent increase.
Like other states, New Jersey is facing epidemic levels of hepatitis C infection among inmates. Nationally, 20-30 percent of prisoners are infected with the blood-borne virus. In Georgia, the annual budget for hepatitis C treatment could eventually approach $5 million, said Joseph Paris, the state's prison medical director.
10.31.02; Mark Fazlollah; Jennifer Lin
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|